European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F20%3A00116551" target="_blank" >RIV/00216224:14110/20:00116551 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/20:00073834
Result on the web
<a href="https://www.nature.com/articles/s41375-020-0776-2.pdf" target="_blank" >https://www.nature.com/articles/s41375-020-0776-2.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41375-020-0776-2" target="_blank" >10.1038/s41375-020-0776-2</a>
Alternative languages
Result language
angličtina
Original language name
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Original language description
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia
ISSN
0887-6924
e-ISSN
1476-5551
Volume of the periodical
34
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
19
Pages from-to
966-984
UT code for WoS article
000517861700002
EID of the result in the Scopus database
2-s2.0-85081568026